Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2021-04-07 M&A Activity
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
M&A Activity Classification · 99% confidence The document is a press release ("Communiqué de presse") dated April 7, 2021, announcing that BIOSYNEX has signed a firm offer to acquire 100% of the shares of AVALUN. This is a significant corporate transaction related to M&A activity. The definitions provided include 'M&A Activity (Code: TAR)' for merger proposals or takeover bids. Although the deal is not finalized ("signature de la documentation juridique définitive... est prévue fin avril"), the announcement of a firm offer to acquire another company clearly falls under the scope of M&A Activity (TAR). It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it concerns a specific strategic transaction.
2021-04-07 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces strategic operational updates regarding the authorization and deployment of SARS-CoV-2 self-tests in several EU countries. It is short (2930 characters) and focuses on a business development/operational milestone rather than detailed financial results (like 10-K or IR) or a formal regulatory filing structure. Crucially, it includes a section announcing the 'Prochaine publication : Chiffre d'Affaires du 1er trimestre 2021, le 15 avril 2021, après Bourse' (Next publication: Q1 2021 Revenue, April 15, 2021, after market close). This structure—a press release announcing operational news and simultaneously announcing the date of a future financial report—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing operational news and not the actual financial results themselves, and it is not a standard SEC form, the most appropriate classification is either ER (if the focus was financial highlights, which it isn't) or RNS (Regulatory Filings) as a general announcement. Given the content is a press release about business operations and future reporting dates, RNS is the best fit as a general regulatory/corporate announcement that doesn't fit the specific financial report codes.
2021-03-31 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 98% confidence The document is a press release ("Communiqué de presse") dated March 24, 2021, detailing the "TRES FORTE PROGRESSION DES RESULTATS ANNUELS 2020" (Very strong progression of 2020 annual results). It includes a summary table of consolidated financial figures for 2020 vs 2019, discusses revenue, EBITDA, net income, and proposes a dividend. Although it covers annual results, it is explicitly a press release announcing these results, not the full, audited 10-K report itself. The document mentions that the audit procedures for the 2020 accounts are ongoing ("Les procédures d'audit des comptes 2020 sont en cours"). This format—a high-level summary announcement of annual financial performance released before the full report filing—is characteristic of an Earnings Release (ER). It provides key highlights and financial metrics immediately following the Board's approval of the year-end accounts. FY 2020
2021-03-24 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces validation updates for COVID-19 diagnostic tests (antigenic and PCR). It details regulatory achievements (CE marking extension, inclusion on EU/German lists) and market positioning. Crucially, near the end, it states: "Prochaine publication : Résultats annuels 2020, le 24 mars 2021, après Bourse." This indicates the document itself is an announcement about company news/developments, not the full Annual Report (10-K) or the detailed Interim Report (IR). Since it is a general press release announcing operational and regulatory milestones, and it is not a specific filing like DIRS, DIV, or CAP, it fits best under the general regulatory announcement category, RNS, as a fallback for non-standard corporate news releases, although it shares characteristics with an Earnings Release (ER) by mentioning the upcoming results. However, since it is not the actual earnings release itself, RNS is the most appropriate general classification for a press release detailing operational updates.
2021-02-24 French
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is explicitly titled as a "PRESS RELEASE" dated January 29, 2021, announcing the "great success of its capital increase through placement with qualified investors for an amount of €15m." It details the issuance of new shares, the total amount raised (€14,999,984), the use of proceeds, and the resulting change in share capital structure. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA).
2021-01-29 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is a press release dated January 29, 2021, announcing the 'très vif succès de son augmentation de capital par voie de placement auprès d'investisseurs qualifiés pour un montant de 15 millions d'euros' (very strong success of its capital increase via placement to qualified investors for an amount of 15 million euros). The text details the issuance of new shares, the total amount raised, the resulting change in share capital structure, and the intended use of the funds. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (Code: CAP). It is not a general regulatory filing (RNS) because it is highly specific, nor is it an announcement of a report (RPA).
2021-01-29 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.